Sponsor or institution
Clinical trials and research at ViiV Healthcare
As of November 12, 2026, Find a Trial lists 11 clinical trials run by ViiV Healthcare that are recruiting, at sites in 20 countries (most in United States (8), Argentina (2), Australia (2)). By phase: Phase 1 (6), Phase 1/2 (2), Phase 3 (2), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 11Clinical trials
- 20Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| VH4367310 in healthy adults: testing single increasing doses for safety and how it behaves in the body | Phase 1 | Glendale, California and 1 other locations | Recruiting | Sep 14, 2026 |
| Cabotegravir and Rilpivirine Ultra Long-Acting in people with HIV who are virologically suppressed | Phase 3 | Phoenix, Arizona and 110 other locations | Recruiting | Jun 16, 2026 |
| Mass Balance and Oral Bioavailability of a radiolabeled HIV drug | Phase 1 | Groningen | Recruiting | Jun 9, 2026 |
| First-in-human test of VH4770359 in healthy adults | Phase 1 | Baltimore, Maryland | Recruiting | Apr 13, 2026 |
| Continued access for people who benefited from ViiV HIV treatment after parent studies | Phase 3 | Durban, KwaZulu-Natal and 3 other locations | Recruiting | Feb 6, 2026 |
| Cabotegravir for HIV-exposed newborns | Phase 1/2 | Parow Valley | Recruiting | Dec 10, 2025 |
| Phase 2b testing of oral VH4524184 regimens for adults with untreated HIV‑1 | Phase 2 | Bakersfield, California and 122 other locations | Recruiting | Oct 2, 2025 |
| Assessing the safety and pharmacokinetics of VH4011499 in healthy adults | Phase 1 | Las Vegas, Nevada and 1 other locations | Recruiting | Dec 9, 2024 |
| Testing a new long-acting treatment for HIV | Phase 1 | Lenexa, Kansas and 4 other locations | Recruiting | Mar 15, 2024 |
| Evaluating a new HIV treatment for children | Phase 1/2 | Long Beach, California and 7 other locations | Recruiting | Jan 6, 2023 |
All recruiting trials (11)
-
VH4367310 in healthy adults: testing single increasing doses for safety and how it behaves in the body
This study tests a single rising dose of VH4367310, a cabotegravir prodrug, to see how it behaves in the body and how safe and tolerable it is in healthy adults aged 18 to 55.
-
Cabotegravir and Rilpivirine Ultra Long-Acting in people with HIV who are virologically suppressed
This study tests if ultra-long-acting cabotegravir and rilpivirine given with their long-acting partners can maintain suppression in adults and adolescents who are already virologically suppressed on ART.
-
Mass Balance and Oral Bioavailability of a radiolabeled HIV drug
This early-phase study tests how the radiolabeled VH4524184 is absorbed, distributed, metabolized, and excreted in adults with HIV.
-
First-in-human test of VH4770359 in healthy adults
This early study will see if VH4770359 is safe and well tolerated in healthy adults and how the body processes it.
-
Continued access for people who benefited from ViiV HIV treatment after parent studies
This study lets people who benefited from a ViiV HIV treatment continue receiving it if they don’t have local access after completing a parent study.
-
Cabotegravir for HIV-exposed newborns
This study tests cabotegravir in newborns exposed to HIV to see if a preventive regimen is safe and tolerable.
-
Phase 2b testing of oral VH4524184 regimens for adults with untreated HIV‑1
This trial will test whether two doses of a new oral medicine, VH4524184 taken with FTC/TAF, can suppress HIV‑1 as well as the standard DTG/3TC treatment in adults who have never received antiretroviral therapy.
-
Assessing the safety and pharmacokinetics of VH4011499 in healthy adults
This study is testing a new drug called VH4011499 to see if it's safe and how it works in healthy adults aged 18 to 55.
-
Testing a new long-acting treatment for HIV
This study is testing a new long-acting injection for HIV to see if it's safe and how well it works in healthy adults.
-
Evaluating a new HIV treatment for children
This study is testing a new combination HIV treatment for children aged 6 to under 12 who are already managing their virus well, to see if it is safe and effective for them.
-
Investigating a new long-acting HIV treatment in healthy adults
This study is testing a new long-acting HIV treatment in healthy adults to see how safe it is and what the best dose might be for future use.
Quick answers
How many clinical trials run by ViiV Healthcare are recruiting right now?
11, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 20 countries. The most sites are in United States (8 trials), Argentina (2 trials), Australia (2 trials), Canada (2 trials), Japan (2 trials). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 6, Phase 1/2: 2, Phase 3: 2, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.